RESUMEN
Modified ultrafiltration (MUF) is a technique which is commonly used immediately post-cardiopulmonary bypass (CPB) for open heart surgery in children. There are many advantages of MUF, but there are also a number of less reported disadvantages. At our institution, after considering all of the available data, a decision was made to no longer perform MUF. The primary motivation being the simplified and miniaturized CPB circuit would reduce hemodilution, decrease our likelihood of reaching our transfusion trigger during CPB and, potentially, improve safety. This study reports the before and after data from this practice change. A total of 160 patients less than 8kg were studied over 38 months and divided into neonatal and pediatric cohorts. Parameters reported in this study include: demographics, hematocrit, blood product transfusion, hemostasis, hemodynamics and outcomes. Although retrospective, our analysis supports an advantage of preventing hemodilution (via circuit miniaturization) versus reversing hemodilution (via MUF) at our institution with the patient population we examined.
Asunto(s)
Puente Cardiopulmonar/métodos , Paro Cardíaco Inducido/métodos , Ultrafiltración/métodos , Transfusión Sanguínea , Puente Cardiopulmonar/instrumentación , Diseño de Equipo , Paro Cardíaco Inducido/instrumentación , Hematócrito , Hemodinámica , Hemostasis , Humanos , Lactante , Recién Nacido , Estudios Retrospectivos , Ultrafiltración/instrumentaciónRESUMEN
BACKGROUND: Current blood pumps used for cardiopulmonary bypass generally fall into two different pump design categories; non-occlusive centrifugal pumps and occlusive, positive-displacement roller pumps. The amount of foreign surface area of extracorporeal circuits correlates with post-operative morbidity due to systemic inflammation, leading to a push for technology that reduces the amount of foreign surfaces. Current roller pumps are bulky and the tubing forms an arc in the pumping chamber (raceway), positioning the inlet 360 degrees from the outlet, making it very difficult to place the pump closer to the patient and to efficiently reduce tubing length. These challenges put existing roller pumps at a disadvantage for use in a compact cardiopulmonary bypass circuit. Centrifugal blood pumps are easier to incorporate into miniature circuit designs. However, the prime volumes of current centrifugal pump designs are large, especially for pediatric extracorporeal circuits where the prime volumes are too great to be of clinical value. METHOD: We describe a preliminary report on a novel, occlusive, linear, single-helix, positive-displacement blood pump which allows for decreased prime volume and surface area of the extracorporeal circuit. This new experimental pump design was used to perfuse a 6 kilogram piglet with a pediatric cardiopulmonary bypass circuit for two hours of continuous use. Blood samples were obtained every thirty minutes and assayed for plasma free hemolysis generation. CONCLUSIONS: The results from this initial experiment showed low plasma free hemoglobin generation and encourages the authors to further develop this concept.
Asunto(s)
Puente Cardiopulmonar/instrumentación , Puente Cardiopulmonar/métodos , Corazón Auxiliar , Animales , Femenino , Hemólisis , PorcinosRESUMEN
There have been numerous recent advances geared specifically toward the practice of pediatric cardiopulmonary bypass (CPB). These advances include the development of the first oxygenator intended solely for the neonatal CPB patient; pediatric oxygenators with low prime volumes and surface areas, which allow flows up to 2 L/min; pediatric oxygenators with integrated arterial filters; and miniature ultrafiltration (UF) devices, which allow for high rates of ultrafiltrate removal. When used in combination with heart lung machines with mast-mounted pumps, these advances can result in significant decreases in CPB circuit surface areas and prime volumes. This may attenuate CPB-associated hemodilution and decrease or eliminate the need for homologous red blood cells during or after CPB. In addition to these equipment-related advances, changes in myocardial protection strategies and the technique of modified UF as it relates to these advances are discussed.
Asunto(s)
Puente Cardiopulmonar/métodos , Niño , Paro Cardíaco Inducido , Humanos , Oxigenadores , UltrafiltraciónRESUMEN
UNLABELLED: The timing of blood product administration after cardiopulmonary bypass (CPB) may influence the amount of postoperative transfusion and chest tube output. We performed a retrospective study of a novel technique of administering blood products during modified ultrafiltration (MUF) in congenital cardiac surgery. A Control Group (CG; n = 55) received cryoprecipitate and platelets after modified ultrafiltration. The Treatment Group (TG; n = 59) received cryoprecipitate and platelets during MUF. Volumes of blood products transfused in the operating room, initial coagulation parameters in the cardiac intensive care unit, and first 24-hour chest tube output were recorded. Age (116 +/- 198 versus 84 +/- 91 days), weight (4.6 +/- 1.8 versus 4.5 +/- 1.4 kg), duration of bypass (121 +/- 50 versus 139 +/- 57 minutes), and Aristotle scoring (9.3 +/- 2.7 versus 9.1 +/- 3.1) were not significantly different when comparing the control and treatment groups, respectively. Intraoperative packed red blood cells (74.4 +/- 34.8 versus 79.3 +/- 58.0 mL/kg, p = .710), fresh-frozen plasma (58.3 +/- 27.1 versus 59.1 +/- 27.2 mL/kg, p = .849), cryoprecipitate (7.3 +/- 5.1 versus 8.6 +/- 5.9 mL/kg, p = .109), and platelet (19.0 +/- 14.6 versus 23.7 +/- 20.8 mL/kg, p = .176) administration were the same in the control and treatment groups, respectively. However, fibrinogen levels on arrival in the coronary intensive care unit were significantly higher (305 +/- 80 versus 255 +/- 40 mg/dL, p < .001) in the CG compared with the TG. Twenty-four-hour chest tube output was not significantly different but the CG (17.76 +/- 9.34 mL/kg/24 hours) was trending lower than the TG (19.52 +/- 10.94 mL/kg/24 hours, p = .357). In an attempt to minimize CPB-associated bleeding and transfusions, we changed our practice by adjusting the timing of blood product administration after patient separation from CPB. The goals of the change in practice were not measurably different in terms of shorter intraoperative times, fewer blood transfusions, or less chest tube output at our institution. KEYWORDS: congenital heart disease, modified ultrafiltration, cryoprecipitate, platelets, cardiopulmonary bypass.
Asunto(s)
Puente Cardiopulmonar/instrumentación , Factor VIII/administración & dosificación , Fibrinógeno/administración & dosificación , Cardiopatías Congénitas/enfermería , Cardiopatías Congénitas/cirugía , Hemofiltración/instrumentación , Transfusión de Plaquetas/instrumentación , Diseño de Equipo , Análisis de Falla de Equipo , Femenino , Humanos , Lactante , MasculinoRESUMEN
BACKGROUND: The utility of procalcitonin (PCT) and C-reactive protein (CRP) as infectious biomarkers following infant cardiothoracic surgery is not well defined. METHODS: We designed a prospective cohort study to evaluate PCT and CRP after infant cardiothoracic surgery. PCT and CRP were drawn preoperatively and 24/72 h postoperation or daily in delayed sternal closure patients. Presence of infection within 10 d of surgery, vasoactive-inotropic scores at 24 and 72 h, and length of intubation, intensive care unit stay, and hospital stay were documented. RESULTS: PCT and CRP were elevated at 24 h. PCT then decreased while CRP increased in patients undergoing delayed sternal closure or cardiopulmonary bypass. In the delayed sternal closure group, PCT was significantly higher on postoperative days 2-5 in patients who ultimately developed infection. Higher PCT was independently associated with increased vasoactive-inotropic score at 72 h. CRP did not correlate with infection or postoperative support. CONCLUSION: PCT rises after cardiothoracic surgery in infants but decreases by 72 h while CRP remains elevated. Sternal closure may affect CRP but not PCT. PCT is independently associated with circulatory support requirements at 72 h postoperation and with development of infection. PCT may have greater utility as a biomarker in this population.
Asunto(s)
Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Calcitonina/sangre , Procedimientos Quirúrgicos Cardiovasculares/efectos adversos , Complicaciones Posoperatorias/sangre , Precursores de Proteínas/sangre , Sepsis/sangre , Análisis de Varianza , Péptido Relacionado con Gen de Calcitonina , Estudios de Cohortes , Humanos , Lactante , Recién Nacido , Cinética , Modelos Lineales , Pruebas de Función Hepática , Estudios Prospectivos , Estadísticas no Paramétricas , Factores de TiempoRESUMEN
BACKGROUND: Rapid-response extracorporeal membrane oxygenation (RR-ECMO) has been implemented at select centers to expedite cannulation for patients placed on ECMO during extracorporeal cardiopulmonary resuscitation (ECPR). In 2008, we established such a program and used it for all pediatric venoarterial ECMO initiations. This study was designed to compare outcomes before and after program implementation. METHODS: Between 2003 and 2011, 144 pediatric patients were placed on venoarterial ECMO. Records of patients placed on ECMO before (17 ECPR and 62 non-ECPR) or after (14 ECPR and 51 non-ECPR) RR-ECMO program implementation were retrospectively compared. RESULTS: The peak performance of the ECMO team was assessed by measuring ECMO initiation times for the ECPR patient subgroup (n = 31). There was a shift toward more ECPR initiations achieved in less than 40 minutes (24% pre-RR-ECMO versus 43% RR-ECMO; p = 0.25) and fewer requiring more than 60 minutes (47% pre-RR-ECMO versus 21% RR-ECMO; p = 0.14) after program implementation, although these changes did not reach statistical significance. After multivariable risk adjustment, RR-ECMO was associated with a 52% reduction in neurologic complications for all patients (adjusted odds ratio, 0.48; 95% confidence interval, 0.23 to 0.98; p = 0.04), but the risk of in-hospital death remained unchanged (adjusted odds ratio, 0.99; 95% confidence interval, 0.50 to 1.99; p = 0.99). CONCLUSIONS: Implementation of a pediatric RR-ECMO program for venoarterial ECMO initiation was associated with reduced neurologic complications but not improved survival during the first 3 years of program implementation. These data suggest that development of a coordinated system for rapid ECMO deployment may benefit both ECPR and non-ECPR patients, but further efforts are required to improve survival.
Asunto(s)
Oxigenación por Membrana Extracorpórea/mortalidad , Oxigenación por Membrana Extracorpórea/métodos , Paro Cardíaco/terapia , Mortalidad Hospitalaria/tendencias , Equipo Hospitalario de Respuesta Rápida/organización & administración , Reanimación Cardiopulmonar/métodos , Preescolar , Estudios de Cohortes , Bases de Datos Factuales , Femenino , Estudios de Seguimiento , Implementación de Plan de Salud/organización & administración , Paro Cardíaco/mortalidad , Cardiopatías Congénitas/diagnóstico , Cardiopatías Congénitas/mortalidad , Cardiopatías Congénitas/cirugía , Humanos , Lactante , Masculino , Pediatría/organización & administración , Desarrollo de Programa , Evaluación de Programas y Proyectos de Salud , Mejoramiento de la Calidad , Estudios Retrospectivos , Medición de Riesgo , Análisis de Supervivencia , Resultado del Tratamiento , Estados UnidosRESUMEN
INTRODUCTION: Limited evidence suggests that serum alkaline phosphatase activity may decrease after cardiac surgery in adults and children. The importance of this finding is not known. Recent studies, however, have identified a potential role for alkaline phosphatase as modulator of inflammation in multiple settings, including during adult cardiopulmonary bypass. We sought to describe the change in alkaline phosphatase activity after cardiothoracic surgery in infants and to assess for a correlation with intensity and duration of post-operative support, markers of inflammation, and short-term clinical outcomes. METHODS: Sub-analysis of a prospective observational study on the kinetics of procalcitonin in 70 infants (≤ 90 days old) undergoing cardiothoracic surgery. Subjects were grouped based on the use of cardiopulmonary bypass and delayed sternal closure. Alkaline phosphatase, procalcitonin, and C-reactive protein (CRP) levels were obtained pre-operation and on post-operative day 1. Mean change in alkaline phosphatase activity was determined in each surgical group. Generalized linear modeling and logistic regression were employed to assess for associations between post-operative alkaline phosphatase activity and post-operative support, inflammation, and short term outcomes. Primary endpoints were vasoactive-inotropic score at 24 hours and length of intubation. Secondary endpoints included procalcitonin/CRP levels on post-operative day 1, length of hospital stay, and cardiac arrest or death. RESULTS: Mean decrease in alkaline phosphatase was 30 U/L (p = 0.01) in the non-bypass group, 114 U/L (p < 0.0001) in the bypass group, and 94 U/L (p < 0.0001) in the delayed sternal closure group. On multivariate analysis, each 10 U/L decrease in alkaline phosphatase activity on post-operative day 1 was independently associated with an increase in vasoactive-inotropic score by 0.7 (p < 0.0001), intubation time by 6% (p < 0.05), hospital stay by 5% (p < 0.05), and procalcitonin by 14% (P < 0.01), with a trend towards increased odds of cardiac arrest or death (OR 1.3; p = 0.06). Post-operative alkaline phosphatase activity was not associated with CRP (p = 0.7). CONCLUSIONS: Alkaline phosphatase activity decreases after cardiothoracic surgery in infants. Low post-operative alkaline phosphatase activity is independently associated with increased procalcitonin, increased vasoactive/inotropic support, prolonged intubation time, and prolonged hospital stay. Alkaline phosphatase may serve as a biomarker and potential modulator of post-operative support and inflammation following cardiothoracic surgery in infants.
Asunto(s)
Fosfatasa Alcalina/sangre , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Inflamación/enzimología , Cuidados Posoperatorios , Procedimientos Quirúrgicos Torácicos/efectos adversos , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Calcitonina/sangre , Péptido Relacionado con Gen de Calcitonina , Cardiotónicos/uso terapéutico , Femenino , Humanos , Lactante , Recién Nacido , Inflamación/etiología , Intubación Intratraqueal , Tiempo de Internación , Masculino , Estudios Prospectivos , Precursores de Proteínas/sangreRESUMEN
The use of smaller cannulae for minimally invasive surgery techniques and/or aggressive miniaturization of the cardiopulmonary bypass (CPB) circuitry has necessitated the need to augment venous drainage to achieve adequate flow rates. Vacuum assisted venous drainage (VAVD) has become the dominant method to augment venous drainage. VAVD, however, has been associated with a number of known side effects including increased transmission of gaseous microemboli to the patient, venous line chatter, and increased arterial to venous shunts in the circuit. Historically, our practice has been to monitor the arterial output flow rate and to monitor VAVD by observing venous line chatter and changes in the venous reservoir level. In 2008 our pediatric cardiothoracic service began monitoring venous line flow rates by using a second ultrasonic flow probe placed on the venous line. After 12 months, our staff perfusionists reviewed the impact of monitoring venous line flow rates on VAVD and its known side effects on daily clinical practice. When monitoring venous line flow rates, empiric observation revealed that less overall vacuum pressure was needed for our CPB cases. This novel approach to monitoring venous drainage has aided us in providing optimal vacuum levels and therefore, may reduce some of the known side effects experienced with excessive VAVD.
Asunto(s)
Puente Cardiopulmonar/métodos , Ultrasonido/instrumentación , Venas/fisiología , Velocidad del Flujo Sanguíneo , Puente Cardiopulmonar/instrumentación , Humanos , SucciónRESUMEN
In early 2008, surveys of active extracorporeal membrane oxygenation (ECMO) centers in North America were conducted by electronic mail regarding neonatal ECMO equipment and professional staff. Eighty of 103 (78%) North American ECMO centers listed in the Extracorporeal Life Support Organization directory as neonatal centers responded to the survey. Of the responding centers, 82.5% routinely used roller pumps for neonatal ECMO, and the remaining 17.5% used centrifugal pumps. Silicone membrane oxygenators were used by 67% of the respondents, whereas 19% used micro-porous hollow fiber oxygenators, and 14% used polymethylpentene hollow fiber oxygenators. Of the silicone membrane oxygenator users, 86% used the Medtronic Ecmotherm heat exchanger, 10% used the Gish HE-4 heat exchanger, and 4% used the Terumo Conducer device. Sixty-four percent of the responding centers used some form of in-line blood gas monitoring. Six percent of the centers used a bubble trap in the arterial line, and 5% used an arterial line filter. A bladder was used by 85% of the centers, and 4% of these used a mechanical bladder box for servo regulation; the remaining 96% used pressure servo regulation. An air bubble detector was used by 88% of the responding centers. A surface coating was used by 44% of the centers on all their neonatal ECMO patients. Thirty-one percent of the centers use an activated clotting time of 180-220 seconds. At 54% of the responding centers, perfusionists were involved with the ECMO program, registered nurses were involved at 70% of the centers, and respiratory therapists were involved at 46% of the centers. Compared with a 2002 survey, silicone membrane use is declining, and the use of centrifugal blood pumps and coated ECMO circuits is becoming more apparent. ECMO teams are still multidisciplinary, made up of combinations of registered nurses, respiratory therapists, and perfusionists.
Asunto(s)
Oxigenación por Membrana Extracorpórea/instrumentación , Oxigenación por Membrana Extracorpórea/estadística & datos numéricos , Cuidado Intensivo Neonatal/estadística & datos numéricos , Cuidados para Prolongación de la Vida/estadística & datos numéricos , Grupo de Atención al Paciente/estadística & datos numéricos , Recolección de Datos , América del NorteRESUMEN
The purposes of this study were to quantify the insensible water loss that occurs across the Medtronic Minimax oxygenator and to estimate the resultant rise in fluid sodium concentration.A Carmeda-coated extracorporeal membrane oxygenation circuit connected to a Medtronic Minimax Plus oxygenator was primed with normal saline and attached to a closed reservoir. The gas sweep was randomly assigned to one of three rates: 2, 5, or 10 LPM (liters per minute). Each sweep rate was run in triplicate. The sodium concentration of the circuit was assessed after 12 and 24 hours of each trial. At the end of each 24-hour run, the evaporative loss was calculated. The average insensible water losses were 6.9+/-0.4 ml/h, 16.6+/-1.5 ml/h, and 34.4+/-0.3 ml/h at gas sweep rates of 2, 5, and 10 LPM, respectively (p<0.0001). Daily evaporative water losses for the membrane can be estimated to be 82.7+/-2.2 ml for each 1 LPM of sweep gas flow for a normal saline pump flow of 300 ml/min. In a closed circuit, a faster sweep gas rate is associated with a more rapid rise in sodium concentration (p<0.0001).
Asunto(s)
Oxigenación por Membrana Extracorpórea , Pérdida Insensible de Agua , Técnicas In Vitro , Sodio/análisisRESUMEN
Two patients are presented with right atrial tumors, who were considered to be at risk for tumor thrombus migration down the venous line into the cardiopulmonary bypass (CPB) circuit during surgical excision, which may lead to compromised or interrupted venous drainage. An arterial line filter was placed in the venous line to capture any material that might become dislodged and embolize into the circuit. Vacuum-assisted venous drainage, at approximately -50 mmHg, was used to overcome any resistance caused by the filter in the venous line. In one case, tumor thrombus obstructed the filter, requiring the use of the bypass line around the filter, so venous return could be maintained. In both cases, thrombus was found in the filter. The first case was a 44-year-old female (81 kg, 137 cm, body surface area (BSA) 1.66 m2) who presented with a metastatic pheochromocytoma with associated thrombus arising from the left adrenal gland and extending into the inferior vena cava (IVC) and right atrium. The second case was a 37-year-old male (95 kg, 178 cm, BSA 2.17 m2), who presented with a very large angiosarcoma tumor involving almost the entire right atrium. We have shown that venous line filtration with vacuum-assisted venous drainage can be performed safely, and should be considered in cases where there is tumor thrombus in the vena cava or right atrium, which may threaten venous return.
Asunto(s)
Neoplasias Cardíacas/cirugía , Hemangiosarcoma/cirugía , Complicaciones Intraoperatorias/prevención & control , Células Neoplásicas Circulantes , Filtros de Vena Cava , Adulto , Puente Cardiopulmonar/instrumentación , Femenino , Atrios Cardíacos/cirugía , Neoplasias Cardíacas/patología , Hemangiosarcoma/patología , Humanos , Imagen por Resonancia Magnética , Masculino , Vena Cava InferiorRESUMEN
Delays in initiating extracorporeal membrane oxygenation (ECMO) in the critically ill pediatric patient may lead to adverse outcomes. Maintaining a primed ECMO circuit can considerably reduce the initiation time. The predominant concerns precluding this practice are a decrease in oxygenator efficiency due to the saturation of microporous hollow fibers and compromised sterility when the oxygenator has been primed for 30 days. For institutions using a hollow-fiber oxygenator for ECMO, there are no data reporting pre-primed hollow-fiber oxygenator viability. This study reports the efficiency of oxygen transfer and the sterility of the Carmeda Minimax Plus (Medtronic, Inc, Minneapolis, MN) oxygenator after being crystalloid primed for 30 days. A total of 10 Minimax Plus oxygenators were tested for oxygen transfer in a laboratory setting utilizing fresh whole bovine blood. The control group (n =5) were tested immediately after priming. The test group (n =5) were oxygenators primed for 30 days with crystalloid solution and left stagnant until tested. Prior to testing, all oxygenators were circulated for 5 min and samples drawn to test for circuit sterility. Venous inlet saturations were manipulated to achieve three levels of testing: venous saturation (SvO2) of 55% for an oxygen challenge, SvO2 of 65% to comply with AAMI standards, and SvO2 of 75% to assess oxygen transfer rates and peak PaO2 achievement. Blood flow for all tests was maintained at 2 L/min with 1:1 blood to gas flow ratio and 100% FiO2. Samples were drawn pre- and postoxygenator at 1- and 6-hour time intervals to compute actual oxygen transfer values. All cultures from the test group priming solution produced no microbial growth after 30 days of stagnant prime. Average oxygen transfer values (ml/O2/min) for the control group after 1 hour of continuous use were 130.1+/-15.5 (@ 55% SvO2), 113.7+/-10.4 (@ 65% SvO2), 97.7+/-8.9 (@ 75% SvO2). After 6 hours, the average transfer values increased to 134.2+/-13.2 (@ 55% SvO2), 118.76+/-6.6 (@ 65% SvO2) and 98.9+/-8.3 (@ 75% SvO2). The average oxygen transfer values after 1 hour for oxygenators primed for 30 days were 114.9+/-10.0 (@ 55% SvO2), 112.4+/-8.2 (@ 65% SvO2) and 89.6+/-16.0 (@ 75% SvO2). After 6 hours of use, the average transfer values all decreased to 111.4+/-2.1 (@ 55% SvO2, p <0.05 versus control), 104.0+/-5.6 (@ 65% SvO2, p <0.05 versus control) and 88.4+/-3.2 (@ 75% SvO2, p <0.05 versus control). In conclusion, there was a decrease in the average oxygen transfer values for the test group after 6 hours versus the control. The modest loss of oxygen transfer ability observed can be considered acceptable due to the amount of surface area of the Minimax Plus oxygenator when used on a neonate, making it feasible to adopt the practice of prepriming the Minimax oxygenator for neonatal ECMO.
Asunto(s)
Oxigenación por Membrana Extracorpórea/instrumentación , Membranas Artificiales , Oxigenadores de Membrana/normas , Animales , Análisis de los Gases de la Sangre , Bovinos , Soluciones Cristaloides , Contaminación de Equipos , Diseño de Equipo , Humanos , Recién Nacido , Soluciones Isotónicas , Ensayo de Materiales , Modelos Animales , Oxígeno/sangre , Oxigenadores de Membrana/microbiología , Factores de TiempoRESUMEN
OBJECTIVE: As compared with traditional extracorporeal roller-occlusion blood pumps, nonocclusive centrifugal pumps offer the benefits of requiring a smaller circuit surface area and, thus, a smaller prime volume. However, centrifugal blood pumps have been reported to generate unacceptable levels of hemolysis. We hypothesize that the newer generation centrifugal pumps have an incidence of hemolysis similar to the traditional roller head pumps and, thus, could be used for extracorporeal membrane oxygenation circuits. DESIGN: Randomized, prospective, bench study. SETTING: University research laboratory. INTERVENTIONS: Three centrifugal blood pumps (Cobe Revolution, Jostra Rotaflow, and Medtronic BioMedicus) were compared with a roller occlusion blood pump (Cobe Century). Hemolysis generation was examined during 6 hrs of continuous use. Two test runs per group were randomly performed on three consecutive days for a total of six test runs for each of the four pumps (n = 24). MEASUREMENTS AND MAIN RESULTS: Plasma free hemoglobin values were determined using a Spectra MaxPlus spectrophotometer. A normalized index of hemolysis was calculated to compare the individual trials. The Cobe Revolution and the Jostra Rotaflow compared favorably with the Cobe Century roller occlusion blood pump in the amount of hemolysis produced. CONCLUSIONS: These data are encouraging for the development of a low-prime, mobile neonatal extracorporeal membrane oxygenation circuit using centrifugal pump technology.
Asunto(s)
Centrifugación , Oxigenación por Membrana Extracorpórea/instrumentación , Hemólisis , Animales , Velocidad del Flujo Sanguíneo , Presión Sanguínea , Bovinos , Diseño de Equipo , Hemoglobinas/metabolismo , Técnicas In Vitro , Factores de TiempoRESUMEN
Isolated limb perfusion with the administration of cytotoxic drugs has been successfully used to treat melanomas of the extremity since it was first introduced in 1958. The use of hyperthermia (40 degrees C) combined with chemotherapy agents, primarily melphalan, has resulted in greater cytotoxicity in laboratory studies, which led to the application of hyperthermia in clinical studies during the 1960s. The effectiveness of this regional technique and the absence of any good systemic therapy made hyperthermic-isolated limb perfusion (HILP) the main treatment for patients with regionally advanced melanoma. HILP involves open surgical dissection and cannulation of the peripheral vessels and is associated with moderate morbidity rates. Blood transfusions, systemic drug leak, infection, and damage to the blood vessels and nerves are all potential hazards associated with this technique. Recently, however, there has been increased interest in an alternative technique termed isolated limb infusion (ILI), which was first reported in 1994 from the Sydney Melanoma Unit in Australia. Based on a few single institution experiences, it was found that there are fewer morbidities associated with HILP than with ILI but no compromise in patient outcomes. ILI is a less invasive procedure involving the use of angiographically placed catheters inserted percutaneously through the femoral vessels that does not require blood donor exposure or use of a heart lung machine. Preliminary data suggest that the resultant local hypoxia and acidosis induced by this procedure potentiates the cytotoxic effects of melphalan. Response rates comparing ILI to HILP seem similar, and both are markedly better than systemic chemotherapy. ILI may be a more desirable option because morbidity is greatly reduced and outcomes appear similar. There is a potential role for the perfusionist in the application of ILI, an evolving area of cancer therapy.
Asunto(s)
Antineoplásicos Alquilantes/administración & dosificación , Extremidades , Hipertermia Inducida , Melanoma/tratamiento farmacológico , Melfalán/administración & dosificación , Perfusión/métodos , Paro Cardíaco Inducido/instrumentación , Paro Cardíaco Inducido/métodos , HumanosRESUMEN
Given the shortages of banked blood, the risks of transfusion reactions, disease transmissions, and transfusion errors, we perfusionists must find ways to avoid blood transfusions. At the end of any given bypass run, there is residual blood left in the bypass circuit, the perfusionist must get this blood back to the patient. Most commonly either a cell saver or a hemoconcentrator (HC) has been used, in some fashion, to reinfuse residual circuit blood. The ideal method should: 1) be simple; 2) raise the hematocrit (HCT); 3) allow for changes in the patient's volume status; and 4) not compromise the integrity of the cardiopulmonary bypass (CPB) circuit allowing for rapid re-institution of CPB. We describe a technique in which residual CPB circuit blood is pumped through an HC directly to the patient via a 3/16-inch diameter line into a 16-gauge intravenous needle positioned in a peripheral or central vein. This allows the perfusionist to give back concentrated blood that is protein-rich while maintaining the above criteria.
Asunto(s)
Puente Cardiopulmonar/métodos , Oxigenación por Membrana Extracorpórea/métodos , Hemofiltración/métodos , Ultrafiltración/métodos , Pérdida de Sangre Quirúrgica/prevención & control , Recolección de Muestras de Sangre/instrumentación , HumanosAsunto(s)
Cateterismo Venoso Central/efectos adversos , Circulación Cerebrovascular , Puente Cardíaco Derecho , Oxígeno/sangre , Vena Cava Superior , Angioplastia , Puente Cardiopulmonar , Femenino , Humanos , Lactante , Monitoreo Intraoperatorio , Arteria Pulmonar/cirugía , Espectroscopía Infrarroja CortaRESUMEN
In mid 2002, surveys of active extracorporeal membrane oxygenation (ECMO) centers in the United States and Canada were conducted via E-mail regarding neonatal equipment and personnel. Seventy-four out of 99 (75%) North American ECMO centers listed in the Extracorporeal Life Support Organization (ELSO) directory responded to the survey. Of the responding centers, 95% use roller pumps, and the remaining 5% use centrifugal pumps. Silicone membrane oxygenators were used by 97% of the respondents, while 3% used hollow fiber oxygenators. Of the silicone membrane oxygenator users, 82% used the Medtronic ECMOtherm heat exchanger, 15% used a Gish heat exchanger, and 3% used the Dideco D720 heat exchanger. Sixty-one percent of the responding centers used some form of in-line blood gas monitoring. Five percent of the centers used a bubble trap in the arterial line, and 12% used an arterial line filter. A bladder was used by 92% of the centers, and 29% used a mechanical bladder box for servo regulation, the remaining 71% used pressure servo regulation. An air bubble detector was used by 65% of the responding centers, although 81% had the device available. Heparin coating was used by 5% of the centers on all their neonatal ECMO patients. The average low range ACT was 183 seconds, and the average high range ACT was 216 seconds. At 49% of the responding centers, perfusionists were involved with the ECMO program, registered nurses were involved at 84% of the centers, and respiratory therapists were involved at 61% of the centers, perfusion assistants were involved at one center (1%), and biomedical engineers were involved at one of the centers. When compared to a 1990 survey, a shift away from using bladder boxes and toward using air bubble detectors is apparent. But other than those two shifts, ECMO is done in much the same manner as it was done 12 years ago.
Asunto(s)
Oxigenación por Membrana Extracorpórea/instrumentación , Cuidado Intensivo Neonatal , Grupo de Atención al Paciente/estadística & datos numéricos , Anticoagulantes/uso terapéutico , Canadá , Equipos y Suministros de Hospitales/clasificación , Equipos y Suministros de Hospitales/estadística & datos numéricos , Oxigenación por Membrana Extracorpórea/métodos , Oxigenación por Membrana Extracorpórea/estadística & datos numéricos , Encuestas de Atención de la Salud , Humanos , Recién Nacido , Cuidado Intensivo Neonatal/estadística & datos numéricos , Monitoreo Fisiológico/instrumentación , Monitoreo Fisiológico/estadística & datos numéricos , Estudios Prospectivos , Encuestas y Cuestionarios , Estados Unidos , Recursos HumanosRESUMEN
Hemoconcentration is a technique that involves selective removal of plasma water and some dissolved solutes by way of an ultrafiltration membrane. Hemoconcentrators (HC) are routinely used during pediatric cardiopulmonary bypass (CPB) to remove free plasma water and various inflammatory mediators. This paper examines two different commercial HCs, the Dideco DHF0.2 and the Minntech Hemocor HPH 400. Both products were evaluated when used for prebypass ultrafiltration (Pre-BUF), and postbypass modified ultrafiltration (MUF). Five HCs were evaluated for each product, and the two groups were compared during the two different phases of the cardiac procedure. During the pre-BUF period, both groups of HCs were tested at a transmembrane pressure (TMP) gradient of 500 millimeters of mercury (mmHg). The mean amount of ultrafiltrate (UF) removed by the Dideco DHF0.2 was 81.4 milliliters per minute (mL/min), and the mean amount of UF removed by the Minntech Hemocor HPH 400 was 90.8 mL/min during the pre-BUF period. During the peribypass period flow parameters were much harder to define. As a result, these data are not reported. During the MUF procedure, the mean amount of UF removed by the Dideco DHF0.2 was 74.2 mL/min at an average MUF flow rate of 130 mL/min. The mean amount of UF removed by the Minntech Hemocor HPH 400 was 81.4 mL/min at an average MUF flow rate of 127 mL/min. Both products performed adequately under the clinical circumstances described above. The Minntech HPH 400 produced a hemofiltrate that was consistently tinged with a slight red color. The Dideco DHF0.2 consistently produced a hemofiltrate that was noticeably clearer than that of the Minntech device.